Should GLP-1 Receptor Agonists Be Held Before a Gastric Emptying Study?
Yes, GLP-1 receptor agonists should be discontinued for at least three half-lives before a gastric emptying study to obtain accurate baseline results, as these medications fundamentally alter gastric motility through their primary mechanism of action.
Rationale for Discontinuation
GLP-1 receptor agonists delay gastric emptying by inhibiting gastric peristalsis and increasing pyloric tone—this is not a side effect but rather a primary therapeutic mechanism responsible for much of their glucose-lowering effects 1. The drugs work through vagal nerve-mediated pathways on the myenteric plexus, leading to reduced phasic gastric contractions and delayed gastric emptying 1.
Scintigraphy studies (the gold standard for measuring gastric emptying) have consistently demonstrated delayed gastric emptying in patients taking exenatide, liraglutide, and semaglutide 1. This effect persists even with chronic use, though some tachyphylaxis may develop with continuous exposure 1.
Specific Holding Periods
Based on 2024 multidisciplinary consensus guidelines 1:
Hold for at least three half-lives to clear approximately 88% of the drug:
- Semaglutide (weekly): 3 weeks before the study (half-life ~7 days)
- Dulaglutide (weekly): ~2 weeks before the study (half-life ~4.5-4.7 days)
- Tirzepatide (weekly): ~2.5 weeks before the study (half-life ~5 days)
- Liraglutide (daily): 3-4 days before the study (half-life varies by formulation)
Critical Considerations
Why Standard Holding May Be Insufficient
Evidence shows that discontinuation of long-acting drugs for only 7 days did not decrease the prevalence of retained gastric contents and would not ensure an empty stomach 1. This is particularly relevant for gastric emptying studies where you need to measure baseline function without drug interference.
Patient-Specific Factors to Document
Before the study, assess 1:
- Indication and dose of GLP-1 RA (weight loss vs. diabetes management)
- Date drug commenced and last dose taken
- Recent dose changes or new initiation (higher risk of delayed emptying)
- Symptoms of nausea, vomiting, or abdominal distention
- Concomitant medications that delay gastric emptying (opioids, proton pump inhibitors, tricyclic antidepressants)
For Patients with Type 2 Diabetes
Consult with the treating endocrinologist regarding 1:
- Risks and benefits of holding the drug for three half-lives
- Recommendations for bridging diabetic therapy during the holding period to maintain glycemic control
- Alternative glucose management strategies
The benefits of GLP-1 RAs for glycemic control must be weighed against the need for accurate gastric emptying assessment 1.
Common Pitfalls to Avoid
Assuming tachyphylaxis eliminates the effect: While some adaptation occurs with continuous exposure, patients still demonstrate significantly delayed gastric emptying even after prolonged use 1
Using inadequate holding periods: One-day or one-week discontinuation is insufficient for long-acting formulations 1
Failing to account for recent initiation: Acute and intermittent exposure has a more pronounced effect on delaying gastric emptying than continuous long-term infusion 1
Not considering the study's purpose: A gastric emptying study specifically aims to measure baseline gastric function—the presence of a drug that fundamentally alters this function will produce invalid results
Alternative Approach If Holding Is Not Feasible
If the clinical situation requires proceeding without adequate drug clearance, clearly document that the study is being performed on-therapy and interpret results accordingly. The study will reflect gastric emptying under the influence of GLP-1 RA therapy, not baseline function.
The fundamental issue is that GLP-1 RAs are designed to slow gastric emptying—continuing them during a gastric emptying study is analogous to measuring blood pressure while on antihypertensive medication and expecting to see the patient's true baseline pressure.